文献速递肾小球疾病急性肾损伤

抗肾小球基底膜病

Anti-Glomerular Basement Membrane Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-05-17

抗肾小球基底膜(anti-GBM)病是一种罕见的小血管炎,累及肾和肺毛细血管床,由针对基底膜自身抗原的直接致病性自身抗体引起。多数患者出现广泛新月体形成,表现为急进性肾小球肾炎,40%-60%合并肺泡出血。早期采用血浆置换联合激素和细胞毒药物治疗可使多数患者肾脏预后良好,但少尿无尿、高新月体比例或需透析者预后差。

要点

  • 抗GBM病是罕见自身免疫性小血管炎,累及肾肺毛细血管床。
  • 多数患者表现为急进性肾小球肾炎,40%-60%合并肺泡出血。
  • 早期血浆置换联合激素和细胞毒药物可改善多数患者肾脏预后。

核心结论

  • 抗GBM病由直接致病性自身抗体靶向基底膜自身抗原引起,早期联合治疗可改善多数患者肾脏预后。

研究设计与样本

  • 综述性文章,总结抗GBM病的发病机制、临床表现、治疗及预后。

主要发现

  • 近期证实病例存在空间和时间聚集,提示环境因素(包括感染)可能在遗传易感个体中触发疾病。
  • 多数患者出现广泛肾小球新月体形成,表现为急进性GN特征,40%-60%合并肺泡出血。
  • 回顾性队列研究提示早期开始血浆置换联合激素和细胞毒药物治疗时,多数患者肾脏预后良好。
  • 少尿无尿、高比例肾小球新月体或需要透析的肾衰竭提示肾脏预后不良。
  • 肾移植后复发和再发均不常见,但Alport综合征移植后新发抗GBM病是已知现象。

关键数值与推荐

  • 40%-60%的抗GBM病患者合并肺泡出血。

临床怎么用

  • 治疗旨在快速清除致病性自身抗体,通常采用血浆置换,联合激素和细胞毒治疗以阻止自身抗体产生和组织炎症。
  • 早期识别并启动联合治疗对改善肾脏预后至关重要。
  • 出现少尿无尿、高新月体比例或需透析者应警惕不良肾脏预后。

局限性

  • 诱发自身免疫反应的事件尚未完全明了。
  • 需进一步研究免疫致病机制及优化治疗,尤其对不良预后因素患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-glomerular basement membrane (anti-GBM) disease is a rare small vessel vasculitis that affects the capillary beds of the kidneys and lungs. It is an archetypic autoimmune disease, caused by the development of directly pathogenic autoantibodies targeting a well characterized autoantigen expressed in the basement membranes of these organs, although the inciting events that induce the autoimmune response are not fully understood. The recent confirmation of spatial and temporal clustering of cases suggests that environmental factors, including infection, may trigger disease in genetically susceptible individuals. The majority of patients develop widespread glomerular crescent formation, presenting with features of rapidly progressive GN, and 40%-60% will have concurrent alveolar hemorrhage. Treatment aims to rapidly remove pathogenic autoantibody, typically with the use of plasma exchange, along with steroids and cytotoxic therapy to prevent ongoing autoantibody production and tissue inflammation. Retrospective cohort studies suggest that when this combination of treatment is started early, the majority of patients will have good renal outcome, although presentation with oligoanuria, a high proportion of glomerular crescents, or kidney failure requiring dialysis augur badly for renal prognosis. Relapse and recurrent disease after kidney transplantation are both uncommon, although de novo anti-GBM disease after transplantation for Alport syndrome is a recognized phenomenon. Copresentation with other kidney diseases such as ANCA-associated vasculitis and membranous nephropathy seems to occur at a higher frequency than would be expected by chance alone, and in addition atypical presentations of anti-GBM disease are increasingly reported. These observations highlight the need for future work to further delineate the immunopathogenic mechanisms of anti-GBM disease, and how to better refine and improve treatments, particularly for patients presenting with adverse prognostic factors.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol. 2017. PMID: 28515156. doi:10.2215/CJN.01380217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。